Physician profile
Robert E Ebert
NPI 1962436857
$770.78
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.92 · 2020: $158 · 2021: $267 · 2022: $311.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $510.81 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.48 | 2022 | |
| Abbvie INC. | $57.92 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $45.15 | 2022 | |
| Amgen INC. | $31.47 | 2021 | |
| Lilly USA, LLC | $19.65 | 2022 | |
| Astellas Pharma US INC | $18.91 | 2020 | |
| Xeris Pharmaceuticals, INC. | $15.44 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $12.95 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.